George Diaz, MD
Infectious Disease · Everett, WANPI 1164523130
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,200 of the $4,874 with a category attached, or 65.6%. Amgen accounts for 65.6% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $3,740 and has fallen 98.5% since, to $54 in 2022.
Across 7 payments — averaging $696.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Gilead$2K
Across 163 payments — averaging $37,975 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2.8M
- Hoffmann-la Roche Limited$2.2M
- Regeneron$705K
- Boehringer Ingelheim$441K
- Ultragenyx Pharmaceutical Inc.$64K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$1,62033%
- Speaking & faculty fees$3,20066%
- Food & beverage$541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$1,620
How this compares
$4,874 in reported general payments places this provider in the 85th percentile of 186 infectious disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CeftriaxoneCeftriaxone Sodium | 36 | $2,810 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Everett
- Andrew BishopEverett$387
- San WongEverett$305
- Francis RiedoKirkland$183K
- Warren DingesSeattle$173K
- Paul DrainSeattle$149K
- Corey CasperSeattle$115K
- Anna WaldSeattle$103K
- Jim BoonyaratanakornkitSeattle$62K
- Michael BoeckhSeattle$59K
- Jason GoldmanSeattle$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.